MDRNA Names Indication for First IND, Says Early-Stage Collaborations Will Yield Bigger Deals

Separately this week, MDRNA also announced that it has acquired the intellectual property estate covering bridged nucleic acids from Valeant Pharmaceuticals North America, a move that it expects will enhance its ability to develop RNAi and, potentially, non-RNAi therapeutics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories